Home > Neurology > ECF 2020 > ECF Round-Up Articles > Long-term safety and efficacy of ozanimod in relapsing MS

Long-term safety and efficacy of ozanimod in relapsing MS

ECF 2020
In the open-label extension DAYBREAK study, ozanimod was associated with low annualised relapse rate (ARR) and low new and enlarging T2 and gadolinium-enhancing (Gd+) multiple sclerosis (MS) lesion counts over time. Most participants were relapse-free and did not experience disability progression. Ozanimod was generally well tolerated and no new safety concerns emerged with long-term use.  Ozanimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator, has recently been approved for treatment of adults with relapsing forms of MS (FDA) or relapsing-remitting MS (EMA). In controlled phase 3 trials of relapsing MS, ozanimod significantly reduced annualised relapse rate (ARR), new and enlarging T2 and Gd+ lesion count, and brain volume loss compared with interferon-β-1a and was well tolerated. Participants with relapsing MS who completed a phase 1–3 ozanimod trial were eligible for the ongoing open-label extension DAYBREAK study. The objective i...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on